Skip to main content
AmigoFish

Jefferies London: While its in the middle of the closely watched Attruby launch, BridgeBio has two other medicines in front of FDA and another big phase 3 readout scheduled for later next year

From BiotechTV - News · · 9 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Founder & CEO Neil Kumar shares his take on how the Attruby launch is going, and also talks Limb-girdle muscular dystrophy type 2I/R9, achondroplasia, and hypoparathyroidism.

Back to BiotechTV - News · Report a problem